These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 25943554)

  • 1. Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis.
    Siller-Matula JM; Petre A; Delle-Karth G; Huber K; Ay C; Lordkipanidzé M; De Caterina R; Kolh P; Mahla E; Gersh BJ
    Eur Heart J Acute Cardiovasc Care; 2017 Dec; 6(8):753-770. PubMed ID: 25943554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review with meta-analysis: the risk of gastrointestinal bleeding in patients taking third-generation P2Y
    Guo CG; Chen L; Chan EW; Cheung KS; Isshiki T; Wong ICK; Leung WK
    Aliment Pharmacol Ther; 2019 Jan; 49(1):7-19. PubMed ID: 30506985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis.
    Komosa A; Lesiak M; Krasiński Z; Grygier M; Siniawski A; Skorupski W; Olasińska-Wiśniewska A; Pyda M; Araszkiewicz A; Mitkowski P; Grajek S; Mularek-Kubzdela T; Hengstenberg C; Siller-Matula JM
    Thromb Haemost; 2019 Jun; 119(6):1000-1020. PubMed ID: 30919382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there Sex-related Outcome Difference According to oral P2Y12 Inhibitors in Patients with Acute Coronary Syndromes? A Systematic Review and Meta-Analysis of 107,126 Patients.
    Brown O; Rossington J; Buchanan GL; Patti G; Hoye A
    Curr Vasc Pharmacol; 2019; 17(2):191-203. PubMed ID: 29359672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome.
    Bavishi C; Panwar S; Messerli FH; Bangalore S
    Am J Cardiol; 2015 Sep; 116(5):809-17. PubMed ID: 26119655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P2Y
    Lupercio F; Giancaterino S; Villablanca PA; Han F; Hoffmayer K; Ho G; Raissi F; Krummen D; Birgersdotter-Green U; Feld G; Reeves R; Mahmud E; Hsu JC
    Heart; 2020 Apr; 106(8):575-583. PubMed ID: 32034008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
    Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
    Gan XD; Wei BZ; Fang D; Fang Q; Li KY; Ding SL; Peng S; Wan J
    Curr Med Res Opin; 2015 Dec; 31(12):2313-23. PubMed ID: 26402735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y
    Russo JJ; James TE; Ruel M; Dupuis JY; Singh K; Goubran D; Malhotra N; Rubens F; Chong AY; Hibbert B; Boland P; Tran DT; Tanguay JF; Lordkipanidzé M; Perrault L; Wells GA; Bourke M; Chan V; So DY
    Eur Heart J Acute Cardiovasc Care; 2019 Sep; 8(6):543-553. PubMed ID: 29313713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
    Jia M; Li Z; Chu H; Li L; Chen K
    Med Sci Monit; 2015 Apr; 21():1131-7. PubMed ID: 25893318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies.
    Biancari F; Airaksinen KE; Lip GY
    J Thorac Cardiovasc Surg; 2012 Mar; 143(3):665-675.e4. PubMed ID: 21703636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome.
    Shah R; Rashid A; Hwang I; Fan TM; Khouzam RN; Reed GL
    Am J Cardiol; 2017 Jun; 119(11):1723-1728. PubMed ID: 28385176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Potent P2Y
    Wang C; Zhao G; Wang X; Nie S
    Biomed Res Int; 2018; 2018():8572740. PubMed ID: 30648108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel.
    Chen HB; Zhang XL; Liang HB; Liu XW; Zhang XY; Huang BY; Xiu J
    Am J Cardiol; 2015 Aug; 116(3):384-92. PubMed ID: 26051379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
    Held C; Asenblad N; Bassand JP; Becker RC; Cannon CP; Claeys MJ; Harrington RA; Horrow J; Husted S; James SK; Mahaffey KW; Nicolau JC; Scirica BM; Storey RF; Vintila M; Ycas J; Wallentin L
    J Am Coll Cardiol; 2011 Feb; 57(6):672-84. PubMed ID: 21194870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Yudi MB; Clark DJ; Farouque O; Eccleston D; Andrianopoulos N; Duffy SJ; Brennan A; Lefkovits J; Ramchand J; Yip T; Oqueli E; Reid CM; Ajani AE;
    Intern Med J; 2016 May; 46(5):559-65. PubMed ID: 26909472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry.
    Alexopoulos D; Xanthopoulou I; Deftereos S; Hamilos M; Sitafidis G; Kanakakis I; Pentara I; Vavouranakis M; Davlouros P; Hahalis G; Goudevenos J
    J Thromb Haemost; 2016 Jun; 14(6):1146-54. PubMed ID: 26990959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
    Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.